D

Diablo Clinical Research, Inc | Walnut Creek, CO

Research site
(Unclaimed)
Location
2255 Ygnacio Valley Road, Suite M, Walnut Creek, Colorado, United States of America

Site insights

Top conditions

Top treatments

Semaglutide
Tirzepatide
LY3298176
BI 456906
LY3305677
Sugar
LY3841136
Levothyroxine
Tirizepatide
Insulin aspart

Parent organization

This site is a part of Diablo Clinical Research, Inc

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 27 total trials

A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 differen...

Enrolling
Obesity
Drug: Placebo
Drug: Tirzepatide

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling
Type 2 Diabetes
Drug: Semaglutide
Drug: Cagrilintide

This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study....

Active, not recruiting
Obesity
Diabetes Mellitus, Type 2
Drug: Placebo
Drug: Semaglutide

This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the inv...

Active, not recruiting
Obesity
Drug: Placebo
Drug: Semaglutide

This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participan...

Active, not recruiting
Overweight
Type 2 Diabetes Mellitus
Drug: Placebo semaglutide
Drug: Placebo cagrilintide

The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are:* safe; and* how these vaccines produce a...

Enrolling
Influenza, Human
Biological: Influenza ModRNA Vaccine
Biological: Quadrivalent Influenza Vaccine (QIV)

The purpose of this study is to show that high-dose quadrivalent seasonal influenza vaccine (HD QIV) given together with 9-valent extraintestinal pat...

Active, not recruiting
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Biological: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose es...

Active, not recruiting
Type 2 Diabetes
T2D
Drug: Insulin Glargine
Drug: Insulin Efsitora Alfa

The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3305677

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Enrolling
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants th...

Enrolling
Obesity
Drug: Mibavademab-Placebo
Drug: Tirzepatide-Placebo
Locations recently updated

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism a...

Enrolling
Hypothyroidism
Drug: Levothyroxine
Drug: Armour Thyroid

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 d...

Enrolling
Obesity
Diabetes Mellitus, Type 2
Drug: Survodutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have* a body mass index (BMI) of 30 kg/m² or more, or* a BMI of 27 kg/m² or more and a...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

Trial sponsors

Lilly logo
Novo Nordisk logo
Boehringer Ingelheim logo
Merck Sharp & Dohme (MSD) logo
Pfizer logo
AbbVie logo
BioNTech logo
B
J

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems